 |
 |
Well now I ask you.. That ties in with something I heard today from a former NIH doctor, who among other things, accuses the drug-manufacturing companies of blocking legitimate research for a cure for PD because then they would have no market for all their anti-parkinsonian medications! Hilary Blue ___________________________________________________________________ J. R. Bruman wrote: > > Failure to have cabergoline approved for PD therapy, in spite > of its superior value, is apparently a business-related > decision. Upjohn, the firm which introduced cabergoline about > ten years ago, was taken over and absorbed by Pharmacia Inc., > developers of pramipexole (Mirapex), which is just entering the > market at the peak of its patent protection value. Evidently, > the corporate owners don't want competition against Mirapex > from within their own house. Cheers, > Joe > -- > J. R. Bruman (818) 789-3694 > 3527 Cody Road > Sherman Oaks, CA 91403-5013